Applied Therapeutics to be acquired by Cycle Group for $0.088/share plus CVRs worth up to $0.40

Applied Therapeutics, Inc.

Offer price: $0.088 per share cash plus one non-tradeable CVR with up to $0.40 per share in milestone payments.
Milestones include FDA approval for galactosemia ($0.10), CMT-SORD ($0.10), and net sales >= $200M ($0.20).
Parent provides up to $8.5M unsecured promissory note at 24% interest to fund working capital pending close.
Board unanimously approved; transaction subject to tender of majority of shares and other customary conditions.
Termination fee of $648,000 plus 4.5% of outstanding note principal payable by Applied in certain circumstances.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.6

Applied Therapeutics, Inc. incurred loan of not fully specified in excerpt with not fully specified in excerpt at not fully specified in excerpt maturing not fully specified in excerpt.

Instrument: loan
Principal: not fully specified in excerpt
Counterparty: not fully specified in excerpt
Rate: not fully specified in excerpt
Maturity: not fully specified in excerpt
Event: incurrence

Exact text from the filing

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in Item 1.01 of this report under the caption titled “Unsecured Promissory Note,” including Exhibit 10.1 attached hereto, is incorporated by reference in this Item 2.03.

View on SEC.gov

311 debt financings filed in the last 30 days. Browse all debt financings →

Source: SEC EDGAR

accession 0001193125-25-316607

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.